Indivior (NASDAQ:INDV) Issues Quarterly Earnings Results, Beats Expectations By $0.32 EPS

Indivior (NASDAQ:INDV) posted its earnings results on Thursday. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.32, FiscalAI reports. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The firm had revenue of $317.00 million during the quarter, compared to the consensus estimate of $272.84 million.

Here are the key takeaways from Indivior’s conference call:

• Strong commercial momentum — Q1 total net revenue was $317M (+19% YoY) driven by SUBLOCADE net revenue of $232M (+32% YoY), 20% dispense unit growth, record ~31,800 new patient starts, and over 500,000 U.S. patients prescribed since launch.
• Raised full‑year outlook and margin expansion — management increased 2026 guidance with expected SUBLOCADE revenue $950–990M and Adjusted EBITDA $620–660M (midpoint $640M), targeting a ~51% EBITDA margin driven by unit acceleration and favorable mix.
• Improved balance sheet and capital allocation optionality — completed a $500M convertible note refinancing (reducing interest to 0.625%), repurchased $125M of shares and has roughly $275M remaining on the buyback, while signaling pursuit of commercial‑stage M&A opportunities.
• Pipeline reprioritization and setbacks — INDV‑6001 will not advance to Phase III (rights amended with Alar; Indivior retains U.S. commercial rights) and INDV‑2000 failed its Phase II primary endpoint, so both programs will be de‑emphasized internally and positioned for external business development.

Indivior Stock Up 2.5%

INDV stock traded up $0.92 during midday trading on Friday, hitting $37.70. The company’s stock had a trading volume of 901,843 shares, compared to its average volume of 2,308,607. Indivior has a 52-week low of $10.63 and a 52-week high of $40.02. The firm has a market capitalization of $4.60 billion, a P/E ratio of 22.98 and a beta of 0.88. The firm has a 50-day simple moving average of $31.84 and a 200-day simple moving average of $32.41.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Northland Securities set a $50.00 target price on shares of Indivior in a report on Tuesday, January 20th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Weiss Ratings downgraded shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, March 17th. Finally, HC Wainwright lifted their target price on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Indivior currently has an average rating of “Buy” and an average target price of $39.33.

Insider Buying and Selling

In other Indivior news, Director Stuart A. Kingsley purchased 940 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was bought at an average price of $31.86 per share, with a total value of $29,948.40. Following the transaction, the director directly owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This represents a 20.25% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Indivior

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new position in Indivior in the 3rd quarter valued at approximately $26,000. Raymond James Financial Inc. purchased a new stake in shares of Indivior during the 2nd quarter worth $26,000. Aquatic Capital Management LLC purchased a new stake in shares of Indivior during the 3rd quarter worth $104,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Indivior during the 4th quarter worth $205,000. Finally, Virtus Advisers LLC purchased a new stake in shares of Indivior during the 4th quarter worth $215,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.